NCT00166296View on ClinicalTrials.gov

Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Major Depressive DisorderHepatitis C, Chronic
Interventions
DRUG

Escitalopram

15 mg/day starting 2 weeks before and 12 weeks during interferon therapy

DRUG

Placebo

Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.

Trial Locations (15)

Unknown

Fundacion Hospital Alcorcon, Alcorcón

Hospital Nuestra Señora de Sonsoles, Ávila

Hospital del Mar, Barcelona

Hospital Puerta de Hierro, Madrid

Hospital Ramon y Cajal, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario La Princesa, Madrid

Hospital Parc Tauli, Sabadell

Hospital Universitario de Salamanca, Salamanca

Hospital Consorci Sanitari de Terrassa, Tarrasa

Hospital Clínico Universitario, Valencia

Hospital General Universitario, Valencia

Hospital La Fe, Valencia

Hospital Miguel Servet, Zaragoza

08916

Hospital Universitari Germans Trias i Pujol, Badalona

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Germans Trias i Pujol Hospital

OTHER

NCT00166296 - Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients | Biotech Hunter | Biotech Hunter